Johannes Liebig

TL;DR: The data suggest that pharmacologic inhibition of the CCR1 and/or CCR5 pathways might suppress immune hyperactivation in critical COVID-19, which likely contribute to clinical observations of heightened inflammatory tissue damage, lung injury and respiratory failure.

TL;DR: In this paper, the authors characterized the single-cell transcriptional landscape in the upper airway of SARS-CoV-2-negative and age-matched children and corresponding samples from adults, covering an age range of 4 weeks to 77 years.

TL;DR: In this paper, the authors observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical coronavirus disease 2019 (COVID-19)-related hyperinflammation and increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions.

TL;DR: This study provides novel insights into the pathophysiology of CO VID-19 and suggests an immunomodulatory therapy along the CCL2, CCL3/CCR1 axis as promising option to prevent and treat critical course of COVID-19.

TL;DR: In this article, the authors systematically characterized the single-cell transcriptional landscape in the upper airway in SARS-CoV-2 negative and age-matched SARS CoV2 positive children (n=42) and corresponding samples from adults (n/44) covering an age range of four weeks to 77 years.